Why the study?
Do clofilium phosphate and bretylium tosylate lower ventricular defibrillation threshold in a canine model?
Do clofilium phosphate and bretylium tosylate lower ventricular defibrillation threshold in a canine model?
Clofilium phosphate and bretylium tosylate significantly lower ventricular defibrillation thresholds in a canine model, suggesting potential clinical benefit for controlling ventricular arrhythmias.
Answers are grounded in this paper and cite their sources.
May inform class III agent selection in arrhythmia models; leaves open human defibrillation threshold trials.
This study was conducted to determine the effects of clofilium phosphate and bretylium tosylate on ventricular defibrillation threshold. Dogs were anesthetized with pentobarbital and subjected to repeated fibrillation-defibrillation episodes. Defibrillation thresholds were determined at 15-min intervals, using underdamped 5--6 msec sinusoidal current shocks, from 30 min before drug injection to 120 min after injection. Eight dogs were given clofilium phosphate (0.34 mg/kg, iv). Another 10 dogs were given bretylium tosylate (10.0 mg/kg, iv). Both drugs lowered defibrillation threshold from 15--90 min after injection. The maximum clofilium effect was a 31% decrease in threshold current and a 54% decrease in threshold energy. The greatest decrease in defibrillation threshold produced by bretylium was 16% for current and 31% for energy. These drug induced changes in defibrillation threshold are of potential clinical benefit if they occur in human subjects at doses which are effective for control of ventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
Tacker et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: